TriangleHEALTH PROFESSIONAL · SOURCE READING
Retroperitoneal tumors
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment Option Overview for Soft Tissue Sarcoma / Radiation Therapy
Retrospective data support the use of preRT or PORT versus surgery alone to treat retroperitoneal sarcomas.
Evidence (preRT or PORT vs. surgery alone):
Outcomes from a total of 9,068 patients in two case-control studies conducted between 2003 and 2011 were analyzed.[38]The 2,196 patients who received PORT were compared with 2,196 matched controls.The 563 patients who received preRT were compared with 1,126 matched controls.[38]
Outcomes from a total of 9,068 patients in two case-control studies conducted between 2003 and 2011 were analyzed.[38]The 2,196 patients who received PORT were compared with 2,196 matched controls.The 563 patients who received preRT were compared with 1,126 matched controls.[38]
The median OS was 89 months for the patients in the PORT group versus 64 months for the patients who did not receive radiation therapy.
Outcomes from a total of 9,068 patients in two case-control studies conducted between 2003 and 2011 were analyzed.[38]The 2,196 patients who received PORT were compared with 2,196 matched controls.The 563 patients who received preRT were compared with 1,126 matched controls.[38]
The 5-year survival rate was 60% for the patients in the PORT group and 52% for the patients who did not receive radiation therapy.
Outcomes from a total of 9,068 patients in two case-control studies conducted between 2003 and 2011 were analyzed.[38]The 2,196 patients who received PORT were compared with 2,196 matched controls.The 563 patients who received preRT were compared with 1,126 matched controls.[38]
The median OS was 110 months for the patients who received preRT versus 66 months for the patients who did not receive radiation therapy.
Outcomes from a total of 9,068 patients in two case-control studies conducted between 2003 and 2011 were analyzed.[38]The 2,196 patients who received PORT were compared with 2,196 matched controls.The 563 patients who received preRT were compared with 1,126 matched controls.[38]
The 5-year survival rate was 62% for the patients who received preRT versus 54% for the patients who did not receive radiation therapy.
Two small prospective studies explored the role of neoadjuvant radiation therapy in patients with intermediate- or high-grade retroperitoneal sarcomas. In a combined analysis of the 54 patients who underwent R0 resection (resection for cure or complete remission) or R1 resection (resection to microscopic residual tumor) after preRT, the following results were reported:[39]
Source links and citations
Two small prospective studies explored the role of neoadjuvant radiation therapy in patients with intermediate- or high-grade retroperitoneal sarcomas. In a combined analysis of the 54 patients who underwent R0 resection (resection for cure or complete remission) or R1 resection (resection to microscopic residual tumor) after preRT, the following results were reported:[39]
The 5-year local relapse-free survival (RFS) rate was 60%.
Two small prospective studies explored the role of neoadjuvant radiation therapy in patients with intermediate- or high-grade retroperitoneal sarcomas. In a combined analysis of the 54 patients who underwent R0 resection (resection for cure or complete remission) or R1 resection (resection to microscopic residual tumor) after preRT, the following results were reported:[39]
The 5-year DFS rate was 60%.
Two small prospective studies explored the role of neoadjuvant radiation therapy in patients with intermediate- or high-grade retroperitoneal sarcomas. In a combined analysis of the 54 patients who underwent R0 resection (resection for cure or complete remission) or R1 resection (resection to microscopic residual tumor) after preRT, the following results were reported:[39]
The 5-year OS rate was 61%. The median OS had not been reached (>60 months) at the time of the report.
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice